Irinotecan
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1996
- First approval year
- 1996
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Irinotecan
- Molecular weight
- 586.69
- Structure (SMILES)
- CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC
- (+)-Irinotecan
- biotecan
- Biotecan
- irinophore c
- Irinophore c
- irinotecan
- Irinotecan
- IRINOTECAN [HSDB]
- irinotecan [INN]
- IRINOTECAN [MI]
- IRINOTECAN [VANDF]
- Irinotecan [WHO-DD]
- irinotecan hsdb
- irinotecan inn
- irinotecan mi
- irinotecan vandf
- irinotecan who dd
- nsc 728073
- NSC-728073
- ATC classification codes
- L01CE02
Sources for recorded values
- CAS registry numbers
- 97682-44-5
- ChEMBL ID
- CHEMBL481
- InChIKey
- UWKQSNNFCGGAFS-XIFFEERXSA-N
- PubChem compound IDs
- 60838
- FDA ingredient codes (UNII)
- 7673326042
- 51499
- 153329
- Applicant
- PFIZER INC
- Approval date
- 14 Jun 1996
- Application number
- NDA020571
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- Yes
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- United States (FDA)
- Approved
- Pharmacology name
- irinotecan
- Type
- Synthetic organic
- Drug name stem
- -tecan
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
Open Targets mechanisms
- Mechanism
- DNA topoisomerase I inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase 1
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- TOP1
- Protein identifier
- P11387
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Sarcoma, Ewing
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000174
- Subject identifier
- D012512
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000178
- Subject identifier
- D013274
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Astrocytoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000272
- Subject identifier
- D001254
- Condition
- Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Glioma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000326
- Subject identifier
- D005910
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Ganglioneuroblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000502
- Subject identifier
- D018305
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Glioblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Leukemia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Mesothelioma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000588
- Subject identifier
- D008654
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Neuroblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000621
- Subject identifier
- D009447
- Condition
- Sarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000707
- Subject identifier
- D002294
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001061
- Subject identifier
- D002583
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001075
- Subject identifier
- D010051
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001416
- Subject identifier
- D002583
- Condition
- Astrocytoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002499
- Subject identifier
- D001254
- Condition
- Oligodendroglioma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002501
- Subject identifier
- D009837
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002916
- Subject identifier
- D004938
And 63 more, listed on the interactive page.
- Condition identifier
- EFO_0000174
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000365
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000519
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000621
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000638
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000707
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001061
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001416
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002916
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003833
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003860
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003869
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003891
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003897
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004142
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004288
- Highest recorded phase
- 2
And 173 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Country
- United States
- Event
- abdominal pain
- Reports
- 355
- Reporting signal score
- 118.562
- Event
- alopecia
- Reports
- 226
- Reporting signal score
- 124.108
- Event
- anaemia
- Reports
- 530
- Reporting signal score
- 316.536
- Event
- asthenia
- Reports
- 416
- Reporting signal score
- 107.293
- Event
- bone marrow failure
- Reports
- 141
- Reporting signal score
- 157.869
- Event
- cholinergic syndrome
- Reports
- 35
- Reporting signal score
- 111.067
- Event
- colorectal cancer metastatic
- Reports
- 63
- Reporting signal score
- 210.191
- Event
- decreased appetite
- Reports
- 449
- Reporting signal score
- 333.704
- Event
- dehydration
- Reports
- 293
- Reporting signal score
- 166.862
- Event
- dermatitis acneiform
- Reports
- 86
- Reporting signal score
- 178.998
- Event
- diarrhoea
- Reports
- 1,708
- Reporting signal score
- 1,518.84
- Event
- disease progression
- Reports
- 751
- Reporting signal score
- 1,206.87
- Event
- epistaxis
- Reports
- 186
- Reporting signal score
- 132.573
- Event
- febrile neutropenia
- Reports
- 449
- Reporting signal score
- 599.085
- Event
- gastrointestinal toxicity
- Reports
- 79
- Reporting signal score
- 171.209
- Event
- general physical health deterioration
- Reports
- 216
- Reporting signal score
- 156.622
- Event
- haematotoxicity
- Reports
- 111
- Reporting signal score
- 195.767
- Event
- headache
- Reports
- 82
- Reporting signal score
- 111.307
- Event
- hypertension
- Reports
- 416
- Reporting signal score
- 223.635
- Event
- intestinal obstruction
- Reports
- 111
- Reporting signal score
- 107.923
- Event
- leukopenia
- Reports
- 335
- Reporting signal score
- 401.122
- Event
- malignant neoplasm progression
- Reports
- 293
- Reporting signal score
- 318.133
- Event
- metastases to liver
- Reports
- 142
- Reporting signal score
- 264.602
- Event
- metastases to lung
- Reports
- 75
- Reporting signal score
- 123.029
- Event
- mucosal inflammation
- Reports
- 288
- Reporting signal score
- 471.781
And 12 more, listed on the interactive page.
- NCT00001495
- NCT00044785
- NCT00057473
- NCT00186979
- NCT00193596
- NCT00215501
- NCT00220168
- NCT00249977
- NCT00251407
- NCT00298675
- NCT00502567
- NCT00786669
- NCT00811993
- NCT00861328
- NCT00954512
- NCT00990912
- NCT00993044
- NCT01009073
- NCT01282697
- NCT01593228
- NCT01634555
- NCT01693445
- NCT01916447
- NCT01930552
- NCT02157792
And 519 more, listed on the interactive page.
- Dose
- 125 mg/m2
- Route
- Intravenous
- How often
- Every 6 weeks
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 1
- Polar surface area
- 114.2
- Calculated partition coefficient (ALogP)
- 4.09
- Calculated partition coefficient (XLogP)
- 3
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 4
- Heavy atoms
- 43
- Molecular formula
- C33H38N4O6
- Monoisotopic mass
- 586.27913494
- Natural product
- Yes
- Recorded assays
- 1,877
- Active assays
- 370
- Confirmatory
- Other
- Topoisomerase I Inhibitors
These details could not be displayed.
Related records
Trials (887)
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
- 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
- 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
- 9-ING-41 in Patients With Advanced Cancers
- 9-ING-41 in Pediatric Patients With Refractory Malignancies.
- A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
- A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
- A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer
- A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer
- A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
- A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
- A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
- A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
- A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
- A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
- A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies
- A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors
- A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Approved for (2)
In development for (154)
- Acral lentiginous melanoma Phase 1
- Adenocarcinoma Phase 2
- Ampulla of vater adenocarcinoma Phase 3
- Anaplastic astrocytoma Phase 2
- Anaplastic oligodendroglioma Phase 1
- Angiosarcoma Phase 2
- Appendix cancer Phase 1
- Astrocytoma (excluding glioblastoma) Phase 2
- Atypical teratoid rhabdoid tumor Phase 1
- B-cell chronic lymphocytic leukemia Phase 2
- Bile duct cancer Phase 2
- Bile duct carcinoma Phase 2
- Bile duct neoplasm Phase 2
- Biliary tract cancer Phase 2
- Biliary tract neoplasm Phase 2
- Bladder urachal carcinoma Phase 2
- Bone cancer Phase 2
- Bone neoplasm Phase 2
- Bone sarcoma Phase 2
- Brain cancer Phase 3
Other linked conditions (3)
- Diarrheal disease
- Epithelioid sarcoma
- Pleomorphic xanthoastrocytoma
Targets (1)
- TOP1 DNA topoisomerase I inhibitor